Patents by Inventor Michael C. Goodnough

Michael C. Goodnough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of targeting pharmaceuticals to motor neurons
    Patent number: 6670322
    Abstract: A method of targeting therapeutic molecules to motor neurons is disclosed. In one embodiment, this method comprises the steps of (a) synthesizing a prodrug comprising a therapeutic molecule covalently bound to a polymeric delivery vehicle, and (b) conjugating the prodrug to a botulinum neurotoxin heavy chain.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: December 30, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Michael C. Goodnough, Eric A. Johnson, William H. Tepp, Carl J. Malizio
  • Method of targeting pharmaceuticals to motor neurons
    Publication number: 20030147921
    Abstract: A method of targeting therapeutic molecules to motor neurons is disclosed. In one embodiment, this method comprises the steps of (a) synthesizing a prodrug comprising a therapeutic molecule covalently bound to a polymeric delivery vehicle, and (b) conjugating the prodrug to a botulinum neurotoxin heavy chain.
    Type: Application
    Filed: May 30, 2001
    Publication date: August 7, 2003
    Inventors: Michael C. Goodnough, Eric A. Johnson, William H. Tepp, Carl J. Malizio
  • Chimeric toxins
    Patent number: 6545126
    Abstract: A chimeric toxin is disclosed. In a preferred embodiment, the chimeric toxin comprises a botulinal neurotoxin heavy chain and non-clostridial toxin chain. A method of creating a chimeric toxin is also disclosed. The chimeric toxin will have utility for pharmacological treatment of neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: April 8, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough, Carl J. Malizio, Alan B. Scott
  • Hybrid botulinal neurotoxins
    Patent number: 6444209
    Abstract: A hybrid botulinal neurotoxin is disclosed. In one embodiment, the neurotoxin comprises a combination of a botulinal neurotoxin heavy chain and light chain, wherein the light chain and heavy chain are not of the same serotype and wherein the heavy and light chains are linked by a homobifunctional sulfydryl linker. A method for creating hybrid neurotoxins comprised of different functional domains is also disclosed.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: September 3, 2002
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough, Marite Bradshaw, William H. Tepp
  • Hybrid botulinal neurotoxins
    Patent number: 5939070
    Abstract: A hybrid botulinal neurotoxin is disclosed. In one embodiment, the neurotoxin comprises a combination of a botulinal neurotoxin heavy chain and light chain, wherein the light chain and heavy chain are not of the same serotype. A method for creating hybrid neurotoxins comprised of different functional domains is also disclosed.
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: August 17, 1999
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough, Marite Bradshaw
  • Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
    Patent number: 5756468
    Abstract: Lyophilized pharmaceutical compositions containing botulinum toxin or botulinum neurotoxin and effective amounts of trehalose and methionine have a shelf life of up to 4 months or more at room temperature and above.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: May 26, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough
  • Pharmaceutical composition containing botulinum B complex
    Patent number: 5696077
    Abstract: A pharmaceutical preparation containing a complex consisting of type B botulinum neurotoxin and stabilizing proteins, both derived from C. botulinum, admixed with a pharmaceutically acceptable excipient is provided. The preparation is effective for inducing titratable, local, selective muscle denervation in a patient suffering from a disorder characterized by involuntary muscle spasm or contraction.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: December 9, 1997
    Assignee: Associated Synapse Biologics
    Inventors: Eric A. Johnson, Michael C. Goodnough, Gary E. Borodic
  • Pharmaceutical composition of botulinum neurotoxin and method of preparation
    Patent number: 5512547
    Abstract: Pharmaceutical compositions of botulinum neurotoxin containing higher specific toxicity and increased stability at higher temperatures than currently available preparations.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: April 30, 1996
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough
  • Method for controlling Salmonella enteritidis in poultry
    Patent number: 5132288
    Abstract: In vitro results indicate that trimethoprim may be ineffective against S. enteritides. However, in vivo results show that trimethoprim alone and in combination with polymyxin B sulfate is effective on S. enteritidis infections in poultry.
    Type: Grant
    Filed: April 27, 1990
    Date of Patent: July 21, 1992
    Assignee: Michael Foods, Inc.
    Inventors: Eric A. Johnson, Michael C. Goodnough